Onconic Therapeutics
KOE: 476060.KQ0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- KOSDAQ
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- John Kim
- Employees
- 122
- Headquarters
- Seoul, South Korea
- IPO year
- 2024
- Market cap
- ₩225.8B
- Website
- http://www.onconic.co.kr
Loading 476060…
Loading profile data…Frequently asked questions about 476060
What does Onconic Therapeutics (476060.KQ) do?
Onconic Therapeutics, Inc. is a biopharmaceutical company. It engages in the research and development of new drugs in the field of acid-related diseases and anti cancer. The company was founded on May 7, 2020 and is headquartered in Seoul, South Korea.
Where does 476060.KQ trade?
Onconic Therapeutics (476060.KQ) trades on the KOSDAQ.
What sector is 476060.KQ in?
Onconic Therapeutics (476060.KQ) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Onconic Therapeutics?
John Kim is the chief executive officer of Onconic Therapeutics (476060.KQ).
Where is Onconic Therapeutics headquartered?
Onconic Therapeutics is headquartered in South Korea.
Does 476060.KQ pay a dividend?
Onconic Therapeutics (476060.KQ) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did 476060.KQ go public?
Onconic Therapeutics (476060.KQ) completed its initial public offering in 2024.